Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Needle fasciotomy versus collagenase injection for Dupuytren's disease
ACTRN12618001240235Phase 4Withdrawn
- Sponsor
- Launceston General Hospital
- Start
- Oct 2019
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of collagenase clostridium histolyticum in Dupuytren's contracture (2 arms), sponsored by Launceston General Hospital. Primary endpoints: Change in angle of flexion in the primary randomized joint and Proportion of successful procedures. Planned start Oct 2019; status: withdrawn.
02
Drugs
collagenase clostridium histolyticum
03
Conditions
Dupuytren's contracture
Beyond the preview
Go deeper on ACTRN12618001240235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001240235.